Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilenia Segatto

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Aging|August 24, 2015
Time-tuning cancer therapyGustavo Baldassarre, Ilenia Segatto, Barbara Belletti
International Journal of Molecular Sciences|September 21, 2018
STAT3 in Breast Cancer Onset and Progression: A Matter of Time and ContextIlenia Segatto, Gustavo Baldassarre, Barbara Belletti
Wiley Interdisciplinary Reviews. RNA|May 5, 2021
The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of responseAndrea Favero, Ilenia Segatto, Tiziana Perin, et al.
Frontiers in Cell and Developmental Biology|August 30, 2024
Editorial: Catch me if you can: cellular plasticity in tumor progression and drug resistanceGian Luca Rampioni Vinciguerra, Ilenia Segatto, Julienne L Carstens, et al.
Aging|May 8, 2016
Preclinical validation of a novel compound targeting p70S6 kinase in breast cancerIlenia Segatto, Samuele Massarut, Robert Boyle, et al.
Frontiers in Endocrinology|August 2, 2018
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human TumorsMartina Cusan, Giorgia Mungo, Mara De Marco Zompit, et al.
Cell Division|April 13, 2019
p27kip1 at the crossroad between actin and microtubule dynamicsGian Luca Rampioni Vinciguerra, Francesca Citron, Ilenia Segatto, et al.
Frontiers in Oncology|June 17, 2022
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini ReviewGian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
Cyclin-dependent protein kinases and cell cycle regulation in biology and diseaseIlenia Pellarin, Alessandra Dall'Acqua, Andrea Favero, et al.
Plos One|October 3, 2012
Stathmin is dispensable for tumor onset in miceSara D'Andrea, Stefania Berton, Ilenia Segatto, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Aging|August 24, 2015
Time-tuning cancer therapyGustavo Baldassarre, Ilenia Segatto, Barbara Belletti
International Journal of Molecular Sciences|September 21, 2018
STAT3 in Breast Cancer Onset and Progression: A Matter of Time and ContextIlenia Segatto, Gustavo Baldassarre, Barbara Belletti
Wiley Interdisciplinary Reviews. RNA|May 5, 2021
The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of responseAndrea Favero, Ilenia Segatto, Tiziana Perin, et al.
Frontiers in Cell and Developmental Biology|August 30, 2024
Editorial: Catch me if you can: cellular plasticity in tumor progression and drug resistanceGian Luca Rampioni Vinciguerra, Ilenia Segatto, Julienne L Carstens, et al.
Aging|May 8, 2016
Preclinical validation of a novel compound targeting p70S6 kinase in breast cancerIlenia Segatto, Samuele Massarut, Robert Boyle, et al.
Frontiers in Endocrinology|August 2, 2018
Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human TumorsMartina Cusan, Giorgia Mungo, Mara De Marco Zompit, et al.
Cell Division|April 13, 2019
p27kip1 at the crossroad between actin and microtubule dynamicsGian Luca Rampioni Vinciguerra, Francesca Citron, Ilenia Segatto, et al.
Frontiers in Oncology|June 17, 2022
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini ReviewGian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
Cyclin-dependent protein kinases and cell cycle regulation in biology and diseaseIlenia Pellarin, Alessandra Dall'Acqua, Andrea Favero, et al.
Plos One|October 3, 2012
Stathmin is dispensable for tumor onset in miceSara D'Andrea, Stefania Berton, Ilenia Segatto, et al.
Pageof 4